Namenda
ApprovedSmall molecule
Namenda is one of 55 small molecule programs targeting Liver Cancer. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
261 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Eloxatin
TevaPhase 3
Adriamycin
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Imjudo
AstraZenecaPhase 3
Gemzar
Johnson & JohnsonPhase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Bayer Aspirin
BayerPhase 3
Megace
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Namenda. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SStanford University